|
Originally published In Press as doi:10.1074/jbc.M202291200 on May 13, 2002
J. Biol. Chem., Vol. 277, Issue 29, 26233-26237, July 19, 2002
Effects of Glucose, Exogenous Insulin, and Carbachol on C-peptide
and Insulin Secretion from Isolated Perifused Rat Islets*
Walter S.
Zawalich and
Kathleen C.
Zawalich
From the Yale University School of Nursing,
New Haven, Connecticut 06536-0740
Received for publication, March 8, 2002, and in revised form, May 7, 2002
 |
ABSTRACT |
Isolated perifused rat islets were stimulated
with glucose, exogenous insulin, or carbachol. C-peptide and, where
possible, insulin secretory rates were measured. Glucose (8-10
mM) induced dose-dependent and
kinetically similar patterns of C-peptide and insulin secretion. The
addition of 100 nM bovine insulin had no effect on
C-peptide release in response to 8-10 mM glucose
stimulation. The addition of 100 nM bovine insulin or 500 nM human insulin together with 3 mM glucose had
no stimulatory effect on C-peptide secretion rates from perifused rat
islets. Stimulation with carbachol plus 7 mM glucose
enhanced both C-peptide and insulin secretion, and the further addition
of 100 nM bovine insulin had no inhibitory effect on
C-peptide secretory rates under this condition. Perifusion studies
using pharmacologic inhibitors (genistein and wortmannin) of the
kinases thought to be involved in insulin signaling potentiated 10 mM glucose-induced secretion. The results support the
following conclusions. 1) C-peptide release rates accurately reflect
insulin secretion rates from collagenase-isolated, perifused rat
islets. 2) Exogenously added bovine insulin exerts no inhibitory effect on release to several agonists including glucose. 3) In the presence of
3 mM glucose, exogenously added bovine or human insulin do not stimulate endogenous insulin secretion.
 |
INTRODUCTION |
Insulin secretion from the pancreatic -cell is tightly
regulated by stimulatory signals generated during the intracellular metabolism of glucose and by neurohumoral agonists operative at the
cell membrane (1-5). Most recently an additional layer of complexity
has been added by reports suggesting that insulin exerts an autocrine
stimulatory effect on insulin secretion from the -cell (6, 7). This
concept was based primarily on amperometric measurements using
-cells preincubated in 5-hydroxytryptamine (5HT).1 Because 5HT exposure
exerts inhibitory effects on insulin release (8-10), the precise
physiologic significance of findings made with 5HT-preloaded -cells
is unclear. Moreover, previous studies exploring the potential role of
insulin on stimulated secretion showed no effect (11) or supported the
concept that insulin exerts a negative, not positive, feedback on its
own secretion (12-15).
There are at least three major issues that must be addressed in
attempting to establish the impact of exogenously added insulin on
endogenous insulin secretory rates. The first is technical; it is
difficult to accurately measure endogenous insulin release rates in the
presence of exogenous insulin. The second relates to concentration of
insulin necessary to establish an effect of exogenously added hormone
on the -cell. Considering that the -cell continually releases
insulin into a small volume of interstitial fluid, the level of insulin
bathing the -cell may be quite high. For example, calculations based
on islet cell volume, the insulin diffusion constant and insulin
secretory rates, suggest that these levels may exceed 100 nM during glucose stimulation (16). Even at rest, levels of
insulin far in excess of circulating plasma levels must exist at the
interface of the -cell membrane and the interstitium. Third, the
contribution of constitutive insulin release to the secretory responses
observed has to be considered. The necessary insulin signaling
components identified in insulin-sensitive tissues including insulin
receptors, insulin receptor substrate proteins, and
phosphatidylinositol 3-kinase have been found in -cells
(17-19). Because there is constitutive secretion of insulin, a tonic
level of insulin signaling in these cells may influence acute
stimulatory responses and thus obscure any effect of exogenously added
insulin. These three issues, in addition to the use of different species and disparate methodological approaches, may account in part
for the discrepancies regarding the impact of insulin on its own
secretion (11, 12, 14, 20, 21). To circumvent the first problem, and to
establish the effect of exogenously added insulin on its own secretion,
we have measured connecting (C)-peptide secretion rates in response to
a variety of agonists from isolated perifused rat islets. Finally, the
impact of insulin signaling on 10 mM glucose-induced
secretion was explored using several compounds known to antagonize the
kinases activated by insulin.
 |
EXPERIMENTAL PROCEDURES |
Islet Isolation--
The detailed methodologies employed to
assess insulin output from collagenase-isolated rat islets have been
described previously (22, 23). Male Sprague-Dawley rats (350-475g)
were purchased from Charles River Laboratories, Inc. (Wilmington, MA).
All animals were treated in a manner that complied with the National
Institutes of Health (NIH) Guidelines for the Care and Use of
Laboratory Animals (NIH publication no. 85-23, revised 1985). The
animals were fed ad libitum. After intraperitoneal Nembutal
(pentobarbital sodium, 50 mg/kg; Abbott Laboratories, Abbott Park,
IL)-induced anesthesia, islets were isolated by collagenase digestion
and handpicked, using a glass loop pipette, under a stereomicroscope. They were free of exocrine contamination.
Perifusion Studies--
Groups of 14-18 freshly isolated islets
were perifused with Krebs-Ringer bicarbonate at a flow rate of 1 ml/min
for 30 or 45 min with 3 mM glucose to establish basal and
stable insulin and C-peptide secretory rates. After this stabilization
period they were then perifused with the appropriate agonist or agonist combinations as indicated in the figure legends and under
"Results." Perifusate solutions were gassed with 95%
O2/5% CO2 and maintained at 37 °C. Insulin
(24) and rat C-peptide released into the medium were measured by
radioimmunoassay; in the case of C-peptide measurements the protocol
provided by the vendor was followed rigorously. C-peptide and, when
possible, insulin release rates were measured in the same perifusate samples.
Studies with Cultured Islets--
Groups of 14-18 islets were
cultured as described previously (25, 26) for 18 h in CMRL-1066
containing 5.5 mM glucose and supplemented with penicillin
(50 units/ml), streptomycin (50 µg/ml) and glutamine to achieve a
final concentration of 2 mM. After this, the islets were
perifused as described above.
Reagents--
Hanks' solution was used for the islet isolation.
The Krebs-Ringer bicarbonate perifusion medium consisted of 115 mM NaCl, 5 mM KCl, 2.2 mM
CaCl2, 1 mM MgCl2, 24 mM NaHCO3, and 0.17 g/dl bovine serum albumin.
The 125I-labeled insulin used for the insulin assay was
purchased from PerkinElmer Life Sciences. Bovine serum albumin
(RIA grade), glucose, carbachol, wortmannin, genistein, glutamine,
phorbol 12-myristate 13-acetate (PMA), bovine insulin (Cat. no. I5500),
human recombinant insulin, and the salts used to make the Hanks'
solution and perifusion medium were purchased from Sigma. Genistein and
wortmannin were dissolved in Me2SO, and equivalent amounts
of diluent were used in control studies. Rat insulin standard (lot
615-ZS-157) was the generous gift of Dr. Gerald Gold, Eli Lilly
(Indianapolis, IN). CMRL-1066 and the antibiotics employed for the
culture studies were purchased from Invitrogen. Collagenase (Type P)
was obtained from Roche Molecular Biochemicals. Rat C-peptide was
measured using kits purchased from Linco Research, St. Charles, MO.
Statistics--
Statistical significance was determined using
the Student's t test for unpaired data or analysis of
variance in conjunction with the Newman-Keuls test for unpaired data. A
p value 0.05 was taken as significant. Values presented in
the figure legends and under "Results" represent means ± S.E.
of at least three observations.
 |
RESULTS |
Glucose-induced Insulin and C-peptide Secretion--
In the
initial series of experiments isolated perifused rat islets were
stimulated with 10 mM glucose. Insulin and C-peptide secretory rates were measured in the same perifusate samples. As shown
in Fig. 1, islet responses to 10 mM glucose (in terms of peptide secretory rates) were
kinetically and quantitatively very similar. Both the C-peptide and
insulin responses were biphasic in nature and, when compared with
prestimulatory release rates measured in the presence of 3 mM glucose, the addition of 10 mM glucose
resulted in ~15-fold increments in the output of both peptides.
Similar, although amplified, C-peptide and insulin responses were
obtained when the perifusate glucose level was increased to 15 mM (results not shown).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 1.
Effects of 10 mM glucose
stimulation on C-peptide and insulin secretion. Groups
(n = 4) of 14-18 islets were perifused for 45 min with
3 mM glucose (G3) to establish basal and stable
rates of peptide secretion. They were then stimulated for 45 min with
10 mM glucose (G10) for 30 min, and perifusate
samples were analyzed for C-peptide (closed circles) and
insulin (open circles). Mean values ± S.E. are
depicted in this and all subsequent figures. This and subsequent
figures have not been corrected for the dead space in the perifusion
apparatus, ~2.5 ml or 2.5 min with a flow rate of 1 ml/min.
|
|
Effects of Exogenous Insulin on Glucose-induced C-peptide
Secretion--
In the next experiment, islets were stimulated with 8 mM glucose, a level of the hexose that resulted in a modest
4-5-fold increase in insulin secretory rates (Fig.
2). For example, in the presence of 3 mM glucose islets released 30-35 pg of insulin/islet/min. After 40 min of stimulation with 8 mM glucose, the
secretory rate increased to 143 ± 17 (n = 5)
pg/islet/min. A similar response in terms of C-peptide secretion was
also observed. Prestimulatory secretion rates (5-6 pg/islet/min)
increased to 31 ± 5 pg/islet/min. To assess the potential impact
of exogenous insulin on glucose-induced secretion, additional groups of
islets were stimulated with 8 mM glucose plus 100 nM bovine insulin. The addition of exogenous insulin
precluded the measurement of endogenous insulin secretion. However,
using C-peptide secretion rates as an index of the endogenous insulin
secretory response, no effect of added bovine insulin on C-peptide
secretory rates was seen. 40 min after the onset of 8 mM
glucose stimulation, C-peptide secretory rates averaged 32 ± 3 pg/islet/min in the presence of 100 nM bovine insulin.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 2.
Effects of 8 mM
glucose (G8) and exogenous insulin on C-peptide
secretion rates from isolated perifused islets. Groups
(n = 5) of 14-18 islets were perifused for 45 min with
3 mM glucose (G3) to establish basal and stable
rates of peptide secretion. They were then stimulated for 40 min with 8 mM glucose (closed circles, solid
line) or 8 mM glucose plus 100 nM bovine
insulin (closed circles, dashed line) for 40 min,
and perifusate samples were analyzed for C-peptide. Also depicted are
the insulin secretory responses to 8 mM glucose alone
(open circles).
|
|
Although not shown, we could detect no inhibitory effect of 100 nM bovine insulin on C-peptide responses to 7 or 10 mM glucose, levels of the hexose that increase endogenous
insulin secretion about 2- or 10-15-fold, respectively, above those
observed with 3 mM glucose.
Effects of Exogenous Insulin on Insulin Secretion--
It has been
reported that 100 nM exogenous bovine insulin in the
presence of 3 mM glucose increases insulin secretion from -cells, a response monitored not by the release of insulin but by
5HT release from 5HT-prelabeled -cells (6). We directly tested this
concept in perifused islets, which retain a level of physiologic
sensitivity to glucose stimulation comparable with that observed with
the perfused rat pancreas preparation (27-29). After a 45-min
stabilization period in the presence of 3 mM glucose, islets were perifused with 100 nM bovine insulin or 500 nM human insulin in the continued presence of 3 mM glucose. There was no stimulatory effect of either
insulin preparation on C-peptide secretion rates (Fig.
3). Throughout the perifusion, basal and stable rates of C-peptide secretion were noted.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 3.
C-peptide secretion rates of rat islets
perifused with exogenous insulin. Groups of 14-18 islets were
perifused with 3 mM glucose (G3) for 30 min to
establish stable C-peptide secretion rates and then stimulated with 100 nM bovine insulin (closed circles,
n = 4) or 500 nM human recombinant insulin
(open triangles, n = 3) for 30 min in the
continued presence of 3 mM glucose.
|
|
Carbachol-induced C-peptide and Insulin Secretion--
We
considered that the process of collagenase isolating islets may disrupt
-cell membrane integrity and that the lack of any effect of insulin
on C-peptide secretion may be a consequence of this potential adverse
effect of the isolation procedure. To address this concern, two sets of
additional experiments were conducted. In the first set of experiments
(Fig. 4) islets were stimulated with 7 mM glucose plus 5 µM carbachol, a cholinergic agonist that activates phospholipase C via a membrane muscarinic receptor (30-32). Islets stimulated with 7 mM glucose plus
5 µM carbachol responded with an approximate 4-fold
increase in both insulin and C-peptide secretion rates. The response to
this agonist combination was ~2.5-fold greater than the response to 7 mM glucose alone (results not shown). For example, 20, 30 or 40 min after the onset of stimulation with 7 mM glucose
alone insulin release rates averaged 53 ± 9, 57 ± 10, or
58 ± 12 pg/islet/min (n = 8), respectively. The
addition of carbachol increased the values at these times to 109 ± 29, 125 ± 18, or 126 ± 19 pg/islet/min
(n = 5), respectively. The further addition of 100 nM insulin had no effect on C-peptide secretion to
glucose plus carbachol stimulation (Fig. 4).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 4.
Effects of 7 mM glucose
(G7) plus 5 µM carbachol on
C-peptide and insulin secretion rates. Groups of 14-18 islets
were perifused for 45 min with 3 mM glucose to establish
basal and stable rates of peptide secretion. They were then stimulated
with 7 mM glucose plus 5 µM carbachol plus
(n = 3) or minus (n = 5) the further
addition of 100 nM bovine insulin. Insulin release rates
(open circles), and C-peptide secretion rates (closed
circles, solid line, no added bovine insulin;
closed circles, dashed line, 100 nM
bovine insulin added together with 7 mM glucose plus 5 µM carbachol).
|
|
In the next set of experiments, islets were first cultured for 18 h to allow more complete recovery of any potential adverse impact of
the collagenase isolation procedure. Islets were then perifused with 3 mM glucose to establish basal C-peptide secretion rates
prior to stimulation with 500 nM human insulin. Similar to
the observations made with freshly isolated islets, the addition of
human insulin was without any stimulatory effect on C-peptide secretion
rates. Because culturing impairs islet sensitivity to glucose
stimulation alone (25, 33, 34), these islets were then stimulated with
the combination of 20 mM glucose plus 500 nM
PMA (Fig. 5). This agonist
combination resulted in an ~25-fold increase in C-peptide secretion
rates from both control and prior insulin-stimulated islets.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 5.
C-peptide secretion rates from cultured
islets. Groups of islets were isolated and then cultured for
18 h. One group (open circles, n = 4)
was perifused for 90 min with 3 mM prior to stimulation
with 20 mM glucose plus 500 nM PMA for 20 min.
Only the final 25 min of this perifusion is shown. The second group
(closed circles, n = 3) was perifused for 30 min with 3 mM glucose, 30 min with 3 mM glucose
plus 500 nM human insulin, 30 min with 3 mM
glucose, and 20 min with 20 mM glucose plus 500 nM PMA.
|
|
Effects of Genistein and Wortmannin on Glucose-induced
Release--
In an attempt to disrupt the contribution of constitutive
insulin signaling on glucose-stimulated -cell responses of our perifused islet preparation, additional studies were conducted with the
tyrosine kinase inhibitor genistein (10 µM) and the
phosphatidylinositol 3-kinase inhibitor wortmannin (50 nM).
Both types of kinases are established participants in insulin signaling
(35, 36). As shown in Fig. 6, both
inhibitors significantly potentiated 10 mM glucose-induced
secretion.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 6.
Effects of genistein and wortmannin on
glucose-induced insulin secretion. Groups of 14-18 islets were
perifused with 3 mM glucose (G3) for 30 min.
Islets were then stimulated (indicated by the vertical line)
with 10 mM glucose alone (open circles), 10 mM glucose plus 10 µM genistein (closed
circles, dashed line), or 10 mM glucose
plus 50 nM wortmannin (closed triangles).
The asterisk indicates a significant difference
between the G10 controls and the G10 plus wortmannin- or
genistein-treated islets at this time point.
|
|
 |
DISCUSSION |
Several important considerations have emerged in our attempt to
establish the precise impact of exogenously added insulin on endogenous
insulin secretory rates. First is the realization that the levels of
insulin bathing the -cell, even under basal nonstimulatory
conditions, must far exceed those normally bathing other tissues. This
has to do with islet cell volume, limited interstitial space
distribution, and constitutive rates of hormone output (16). Any
attempt to establish either an inhibitory or excitatory effect of
exogenous insulin on endogenous secretion must contend with this. For
example, if insulin does indeed inhibit its own release as suggested in
other reports (12, 14, 20), an inhibitory effect of added exogenous
insulin on the secretory response to glucose might not be observed if
saturating (with regards to insulin signaling) endogenous hormone
concentrations already exist in the interstitial space and tonically
influence secretion. In addition, it is technically difficult to
measure endogenous insulin release rates in the presence of high levels of exogenously added hormone. In an attempt to circumvent these issues
two approaches were utilized. First, we used C-peptide secretion rates
as a surrogate marker for endogenous insulin secretion (37). Second,
constitutive insulin signaling in the -cell was disrupted using
inhibitors known to interfere with the kinases involved in the insulin
signaling cascade.
Several salient points emerge from the present studies. First,
C-peptide secretion rates accurately reflect both quantitatively and
qualitatively the kinetics and amplitude of insulin secretion. Like
insulin output in response to 10 mM glucose, it is biphasic in nature. Most importantly in terms of sensitivity, small increments in glucose-induced insulin release evoked by 7-8 mM
glucose evoke small, easily measurable increments in C-peptide release.
Third, in terms of inhibition of insulin secretion, we could not detect any inhibitory effect of exogenously added bovine insulin on
glucose-induced insulin secretion. Fourth, neither bovine nor human
insulin at levels of 100-500 nM had any discernible
stimulatory effect on C-peptide secretion rates and, based on the tight
coupling between C-peptide and insulin secretion demonstrated in these
studies, exerted no stimulatory effect on insulin release as well.
Fifth, addition of a membrane-active agonist, carbachol, evoked
substantial insulin and C-peptide responses indicating that at least
for this agonist the functional integrity of its membrane receptor has been maintained during the isolation procedures. However, because the
insulin receptor may be more vulnerable to collagenase than the
muscarinic cholinergic receptor, islets were allowed to recover from
the isolation procedure during an 18-h culturing period. These islets
still failed to respond to exogenously added insulin by increasing
C-peptide secretion rates.
We were unable to document any inhibitory effect of exogenously added
insulin on its own secretion using C-peptide as the surrogate marker
for insulin release. Does this failure exclude an inhibitory effect of
endogenously released insulin on the insulin release process? Does
constitutive insulin secretion tonically influence stimulated
secretion? We attempted to address this issue by using two different
inhibitors known to disrupt the kinases involved in insulin signaling.
Our findings with isolated perifused rat islets confirm the
observations made using mouse islets (38) or neonatal cultured rat
islets (39): genistein is a potentiator of glucose-induced secretion.
Furthermore, our findings also confirm previous studies in both rat
(23, 40) and mouse (41) islets as well as in MIN cells (42);
wortmannin is a potentiator of glucose-induced secretion. Although it
is known that these compounds may interfere with kinases not involved
with insulin signaling and that these effects may complicate the
interpretation of the data, the main point to be made is that these
compounds significantly potentiated glucose-induced release. Whether or
not these inhibitors act as we assume or influence other pathways (43)
still makes these observations noteworthy and the pursuit of the
precise underlying mechanisms involved an important goal for future
studies. The findings also suggest that constitutive secretion may
negatively affect stimulated secretion and that disruption of insulin
signaling in the -cell improves glucose-stimulated insulin secretion.
Our working hypothesis is that constitutive insulin release from
islets, even under nonstimulatory conditions, exerts a tonic inhibitory
effect on stimulated secretion. The addition of exogenous insulin to a
system already tonically inhibited has little further inhibitory effect
as demonstrated here, but its disruption using several inhibitors
markedly improves the secretory performance of the -cell. This
hypothesis is consistent with findings made using knockout mice where
insulin signaling has been disrupted and by pharmacologic inhibition of
kinases thought to be involved in insulin signaling. For example,
islets deficient in the insulin receptor substrate-2 protein or the
p85 regulatory subunit of phosphatidylinositol 3-kinase
hyper-respond to glucose stimulation (41, 44). Of particular
physiologic significance, perhaps, is the observation that basal
secretion is not augmented from these -cells. The impact of these
genetic manipulations becomes manifest only in studies in which glucose
stimulates release. This finding suggests that only under conditions in
which insulin release is stimulated by glucose does insulin signaling
negatively impact release. This situation is analogous to the
2 adrenergic effects in the central nervous system where
presynaptically released catecholamines feed back in a negative fashion
on the cell that released it in order to restrain the secretion of
additional neurotransmitter (45).
Our studies, as well as those of others, using pharmacologic inhibition
of the kinase involved with insulin signaling are also consistent with
the hypothesis that constitutive insulin signaling acts to restrain
stimulated insulin secretion. For example, neither wortmannin nor
genistein potentiates release from islets in the presence of low
nonstimulatory glucose (23, 38). Their positive effect on secretion
only becomes manifest when stimulatory glucose is employed. Although
the specificity of these inhibitors on islet kinases remains to be
determined, it has to be emphasized that these inhibitors reversibly
potentiate glucose-induced insulin secretion, thus ruling out any
untoward nonspecific toxic action. For wortmannin at least, and from a
quantitative perspective, its potentiating effect is comparable with
clinically utilized insulin secretagogues.
Recent interest in the potential role of insulin signaling on -cell
response patterns has been generated largely as a result of studies in
insulin signaling knockout animals (46-48). Amperometric measurements
of 5HT release from normal or abnormal -cells have been used to
support the concept that insulin stimulates its own secretion (6, 7).
Our C-peptide measurements failed to reveal any stimulatory effect of
exogenous insulin on C-peptide release, a surrogate marker of insulin
secretion that accurately reflects small changes in the kinetics and
amplitude of insulin release. The assay used to measure C-peptide
secretion appears sensitive enough to measure small increments in
insulin secretion. For example, the modest 4-5-fold increase in 8 mM glucose-induced release was paralleled by a modest
4-5-fold increase in C-peptide secretion. Even with 7 mM
glucose alone, small but parallel 2-fold increments in both insulin and
C-peptide release were recorded.
In conclusion, C-peptide release rates from perifused rat islets
reflect accurately the kinetics and magnitude of glucose- and
carbachol-induced insulin release. In perifused rat islets, exogenously
added insulin has no inhibitory effect on endogenous insulin secretion
monitored by C-peptide secretion rates. Exogenously added bovine
or human insulin do not stimulate C-peptide release from islets and, by
inference, also fail to exert any autocrine insulin stimulatory effect.
Human insulin failed to affect C-peptide secretion from cultured islets
as well. Known inhibitors of the kinases that participate in insulin
signaling in other tissues significantly amplify glucose-induced
secretion. Although the tonic impact of endogenously released insulin
makes it technically difficult to establish an inhibitory effect of
exogenously added hormone on the release process, any small autocrine
stimulatory effect of added insulin, if it occurred, should have been
readily detected considering the secretory capacity of the -cell and the sensitivity of the C-peptide assay. This was, however, not the case.
 |
ACKNOWLEDGEMENTS |
We thank John Cassidy for helpful comments
and suggestions.
 |
FOOTNOTES |
*
This work was supported by Grant 41230 from the NIDDK,
National Institutes of Health and by the American Diabetes Association.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Yale University School
of Nursing, P.O. Box 9740, 100 Church St. S., New Haven, CT
06536-0740. Tel.: 203-785-5522; Fax: 203-785-6455; E-mail: Walter.Zawalich@Yale.Edu.
Published, JBC Papers in Press, May 13, 2002, DOI 10.1074/jbc.M202291200
 |
ABBREVIATIONS |
The abbreviations used are:
5HT, 5-hydroxytryptamine;
C-peptide, connecting-peptide;
PMA, phorbol
12-myristate 13-acetate.
 |
REFERENCES |
| 1.
|
Henquin, J. C.,
Bozem, M.,
Schmeer, W.,
and Nenquin, M.
(1987)
Biochem. J.
246,
393-399[Medline]
[Order article via Infotrieve]
|
| 2.
|
Malaisse, W. J.,
Sener, A.,
Herchuelz, A.,
and Hutton, J. C.
(1979)
Metabolism
28,
373-386[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Zawalich, W. S.,
and Zawalich, K. C.
(1996)
Am. J. Physiol.
271,
E409-E416[Medline]
[Order article via Infotrieve]
|
| 4.
|
Ashcroft, S. J.
(1980)
Diabetologia
18,
5-15[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Best, L.,
and Malaisse, W. J.
(1984)
Endocrinology
115,
1820-1831[Free Full Text]
|
| 6.
|
Aspinwall, C. A.,
Lakey, J. R. T.,
and Kennedy, R. T.
(1999)
J. Biol. Chem.
274,
6360-6365[Abstract/Free Full Text]
|
| 7.
|
Aspinwall, C. A.,
Qian, W.-J.,
Roper, M. G.,
Kulkarni, R. N.,
Kahn, C. R.,
and Kennedy, R. T.
(2000)
J. Biol. Chem.
275,
22331-22338[Abstract/Free Full Text]
|
| 8.
|
Lernmark, A.
(1971)
Horm. Metab. Res.
3,
305-309[Medline]
[Order article via Infotrieve]
|
| 9.
|
Gagliardino, J. J.,
Nierle, C.,
and Pfeiffer, E. F.
(1974)
Diabetologia
10,
411-414[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Zawalich, W. S.,
Tesz, G. J.,
and Zawalich, K. C.
(2001)
J. Biol. Chem.
276,
37120-37123[Abstract/Free Full Text]
|
| 11.
|
Schatz, H.,
and Pfeiffer, E. F.
(1977)
J. Endocrinol.
74,
243-249[Abstract/Free Full Text]
|
| 12.
|
Iversen, J.,
and Miles, D. W.
(1971)
Diabetes
20,
1-9[Medline]
[Order article via Infotrieve]
|
| 13.
|
Ammon, H. P.,
Reiber, C.,
and Verspohl, E. J.
(1991)
J. Endocrinol.
128,
27-34[Abstract/Free Full Text]
|
| 14.
|
Loreti, L.,
Dunbar, J. C.,
Chen, S.,
and Foà, P. P.
(1974)
Diabetologia
10,
309-315[Medline]
[Order article via Infotrieve]
|
| 15.
|
Sodoyez, J.-C.,
Sodoyez-Goffaux, F.,
and Foà, P. P.
(1969)
Proc. Soc. Exp. Biol. Med.
130,
568-571[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Zawalich, W. S.,
Karl, R. C.,
Ferrendelli, J. A.,
and Matschinsky, F. M.
(1975)
Diabetologia
11,
231-235[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Verspohl, E. J.,
and Ammon, H. P.
(1980)
J. Clin. Invest.
65,
1230-1237[Medline]
[Order article via Infotrieve]
|
| 18.
|
Xu, G. G.,
and Rothenberg, P. L.
(1998)
Diabetes
47,
1243-1252[Abstract]
|
| 19.
|
Harbeck, M. C.,
Louie, D. C.,
Howland, J.,
Wolf, B. A.,
and Rothenberg, P. L.
(1996)
Diabetes
45,
711-717[Abstract]
|
| 20.
|
Ammon, H. P. T.,
and Verspohl, E.
(1976)
Endocrinology
99,
1469-1476[Abstract/Free Full Text]
|
| 21.
|
Rappaport, A. M.,
Ohira, S.,
Coddling, J. A.,
Empey, G.,
Kalnins, A.,
Lin, B. J.,
and Haist, R. E.
(1972)
Endocrinology
91,
168-176[Abstract/Free Full Text]
|
| 22.
|
Zawalich, W. S.,
and Zawalich, K. C.
(2000)
J. Endocrinol.
166,
111-120[Abstract]
|
| 23.
|
Zawalich, W. S.,
and Zawalich, K. C.
(2000)
Endocrinology
141,
3287-3295[Abstract/Free Full Text]
|
| 24.
|
Albano, J. D. M.,
Ekins, R. P.,
Maritz, G.,
and Turner, R. C.
(1972)
Acta Endocrinol.
70,
487-509[Medline]
[Order article via Infotrieve]
|
| 25.
|
Zawalich, W. S.,
Bonnet-Eymard, M.,
Zawalich, K. C.,
and Yaney, G. C.
(1998)
Am. J. Physiol.
274,
C1388-C1396[Medline]
[Order article via Infotrieve]
|
| 26.
|
Zawalich, W. S.,
Zawalich, K. C.,
and Kelley, G. G.
(1996)
Eur. J. Physiol.
432,
589-596[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Gerich, J. E.,
Charles, M. A.,
and Grodsky, G. M.
(1974)
J. Clin. Invest.
54,
833-841[Medline]
[Order article via Infotrieve]
|
| 28.
|
Curry, D. L.
(1986)
Endocrinology
118,
170-175[Abstract/Free Full Text]
|
| 29.
|
Grill, V.,
Adamson, U.,
and Cerasi, E.
(1978)
J. Clin. Invest.
61,
1034-1043[Medline]
[Order article via Infotrieve]
|
| 30.
|
Loubatieres-Mariani, M. M.,
Chapal, J.,
Alric, R.,
and Loubatieres, A.
(1973)
Diabetologia
9,
439-476[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Zawalich, W. S.,
Zawalich, K. C.,
and Rasmussen, H.
(1989)
Endocrinology
125,
2400-2406[Abstract/Free Full Text]
|
| 32.
|
Kelley, G. G.,
Zawalich, K. C.,
and Zawalich, W. S.
(1995)
Am. J. Physiol.
269,
E575-E582[Medline]
[Order article via Infotrieve]
|
| 33.
|
Malaisse-Lagae, F.,
Sener, A.,
and Malaisse, W. J.
(1987)
Acta Diabetol. Lat.
24,
17-25[Medline]
[Order article via Infotrieve]
|
| 34.
|
Metz, S. A.
(1988)
Diabetes
37,
3-7[Abstract]
|
| 35.
|
Virkamäki, A.,
Ueki, K.,
and Kahn, C. R.
(1999)
J. Clin. Invest.
103,
931-943[Medline]
[Order article via Infotrieve]
|
| 36.
|
Pessin, E. J.,
and Saltiel, R. A.
(2000)
J. Clin. Invest.
106,
165-169[Medline]
[Order article via Infotrieve]
|
| 37.
|
Steiner, D. F.
(1977)
Diabetes
26,
322-340[Medline]
[Order article via Infotrieve]
|
| 38.
|
Jonas, J. C.,
Plant, T. D.,
Gilon, P.,
Detimary, P.,
Nenquin, M.,
and Henquin, J. C.
(1995)
Br. J. Pharmacol.
114,
872-880[Medline]
[Order article via Infotrieve]
|
| 39.
|
Sorenson, R. L.,
Brelje, T. C.,
and Roth, C.
(1994)
Endocrinology
134,
1975-1978[Abstract/Free Full Text]
|
| 40.
|
Nunoi, K.,
Yasuda, K.,
Tanaka, H.,
Kubota, A.,
Okamoto, Y.,
Adachi, T.,
Shihara, N.,
Uno, M., Xu, L. M.,
Kagimoto, S.,
Seino, Y.,
Yamada, Y.,
and Tsuda, K.
(2000)
Biochem. Biophys. Res. Commun.
270,
798-805[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Eto, K.,
Yamashita, T.,
Tsubamoto, Y.,
Terauchi, Y.,
Hirose, K.,
Kubota, N.,
Yamahita, S.,
Taka, J.,
Satoh, S.,
Sekihara, H.,
Tobe, K.,
Iino, M.,
Noda, M.,
Kimura, S.,
and Kadowaki, T.
(2002)
Diabetes
51,
87-97[Abstract/Free Full Text]
|
| 42.
|
Hagiwara, S.,
Sakurai, T.,
Tashiro, F.,
Hashimoto, Y.,
Matsuda, Y.,
Nonomura, Y.,
and Miyazaki, J.
(1995)
Biochem. Biophys. Res. Commun.
214,
51-59[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Leahy, J. L.,
and Vandekerkhove, K. M.
(1990)
Endocrinology
126,
1593-1598[Abstract/Free Full Text]
|
| 44.
|
Kubota, N.,
Tobe, K.,
Terauchi, Y.,
Eto, K.,
Yamauchi, T.,
Suzuki, R.,
Tsubamoto, Y.,
Komeda, K.,
Nakano, R.,
Miki, H.,
Satoh, S.,
Sekihara, H.,
Sciacchitano, S.,
Lesniak, M.,
Aizawa, S.,
Nagai, R.,
Kimura, S.,
Akanuma, Y.,
Taylor, S. I.,
and Kadowaki, T.
(2000)
Diabetes
49,
1880-1889[Abstract]
|
| 45.
|
Langer, S. Z.
(1981)
Pharmacol. Rev.
32,
337-362
|
| 46.
|
Kulkarni, R. N.,
Bruning, J. C.,
Winnay, J. N.,
Postic, C.,
Magnuson, M. A.,
and Kahn, C. R.
(1999)
Cell
96,
329-339[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Kulkarni, R. N.,
Winnay, J. N.,
Daniels, M.,
Brüning, J. C.,
Flier, S. N.,
Hanahan, D.,
and Kahn, C. R.
(1999)
J. Clin. Invest.
104,
R69-R75[Medline]
[Order article via Infotrieve]
|
| 48.
| Eto, K., Tsubamoto, Y., Terauchi, Y., Waki, K., Kubota, N., Taka, J.,
Tamemoto, H., Tobe, K., Noda, M., and Kadowaki, T. (2000)
Diabetes 49, (A45)
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. K. Lingohr, I. Briaud, L. M. Dickson, J. F. McCuaig, C. Alarcon, B. L. Wicksteed, and C. J. Rhodes
Specific Regulation of IRS-2 Expression by Glucose in Rat Primary Pancreatic Islet beta-Cells
J. Biol. Chem.,
June 9, 2006;
281(23):
15884 - 15892.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. I. Borelli, F. Francini, and J. J. Gagliardino
Autocrine regulation of glucose metabolism in pancreatic islets
Am J Physiol Endocrinol Metab,
January 1, 2004;
286(1):
E111 - E115.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
B. Wicksteed, C. Alarcon, I. Briaud, M. K. Lingohr, and C. J. Rhodes
Glucose-induced Translational Control of Proinsulin Biosynthesis Is Proportional to Preproinsulin mRNA Levels in Islet {beta}-Cells but Not Regulated via a Positive Feedback of Secreted Insulin
J. Biol. Chem.,
October 24, 2003;
278(43):
42080 - 42090.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Srivastava and H. J. Goren
Insulin Constitutively Secreted by {beta}-Cells Is Necessary for Glucose-Stimulated Insulin Secretion
Diabetes,
August 1, 2003;
52(8):
2049 - 2056.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Briaud, M. K. Lingohr, L. M. Dickson, C. E. Wrede, and C. J. Rhodes
Differential Activation Mechanisms of Erk-1/2 and p70S6K by Glucose in Pancreatic {beta}-Cells
Diabetes,
April 1, 2003;
52(4):
974 - 983.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. Doyle and J. M. Egan
Pharmacological Agents That Directly Modulate Insulin Secretion
Pharmacol. Rev.,
March 1, 2003;
55(1):
105 - 131.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|